Microba Life Sciences Ltd (MAP) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.184x

Based on the latest financial reports, Microba Life Sciences Ltd (MAP) has a cash flow conversion efficiency ratio of -0.184x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-5.70 Million ≈ $-4.04 Million USD) by net assets (AU$31.08 Million ≈ $21.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Microba Life Sciences Ltd's balance sheet to measure how much of total assets are equity-financed.

Microba Life Sciences Ltd - Cash Flow Conversion Efficiency Trend (2018–2024)

This chart illustrates how Microba Life Sciences Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Microba Life Sciences Ltd debt service capacity to assess how comfortably operating cash covers total debt obligations.

Microba Life Sciences Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Microba Life Sciences Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Law Debenture Corp LSE:LWDB	0.023x
Currys PLC LSE:CURY	0.059x
Brilliant Earth Group Inc NASDAQ:BRLT	0.090x
Roctool PA:ALROC	0.523x
SciDev Limited F:INFA	0.025x
Pure Hydrogen Corporation Ltd AU:PH2	-0.252x
VACCITECH (SP.ADR)/1 F:2AB	-0.051x
K-Tech Solutions Company Limited Class A Ordinary Shares NASDAQ:KMRK	N/A

Annual Cash Flow Conversion Efficiency for Microba Life Sciences Ltd (2018–2024)

The table below shows the annual cash flow conversion efficiency of Microba Life Sciences Ltd from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see MAP market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	AU$32.49 Million ≈ $22.99 Million	AU$-12.01 Million ≈ $-8.50 Million	-0.370x	+2.12%
2023-12-31	AU$41.22 Million ≈ $29.16 Million	AU$-15.57 Million ≈ $-11.01 Million	-0.378x	-18.01%
2022-12-31	AU$38.72 Million ≈ $27.40 Million	AU$-12.39 Million ≈ $-8.77 Million	-0.320x	-2.72%
2021-12-31	AU$33.54 Million ≈ $23.73 Million	AU$-10.45 Million ≈ $-7.39 Million	-0.312x	+35.20%
2020-12-31	AU$14.94 Million ≈ $10.57 Million	AU$-7.18 Million ≈ $-5.08 Million	-0.481x	+14.32%
2019-12-31	AU$7.70 Million ≈ $5.45 Million	AU$-4.32 Million ≈ $-3.06 Million	-0.561x	-94.62%
2018-12-31	AU$12.56 Million ≈ $8.88 Million	AU$-3.62 Million ≈ $-2.56 Million	-0.288x	--

About Microba Life Sciences Ltd

AU:MAP Australia Diagnostics & Research

Market Cap

$20.68 Million

AU$29.23 Million AUD

Market Cap Rank

#24999 Global

#1043 in Australia

Share Price

AU$0.05

Change (1 day)

-2.04%

52-Week Range

AU$0.04 - AU$0.10

All Time High

AU$0.44